R. Denis MIYASHIRO, Jose Antonio SANCHES

Cutaneous lymphomas: A review

Non-Hodgkin lenfomalarda cilt etkilenebilir ve gastrointestinal sistemden sonra en sık ikincietkilenenen ekstranodal organ deridir. Kutanöz lenfomalar T, B veya NK lenfositten kökenalabilir. Tanı konulması zordur ve tanınmaları ile yeterli şekilde tedavi olup izleme alınmaları içinhastalığın iyi bilinmesi gerekir. Klinik tablo heterojen olup, tanının doğrulanması için histolojiönemlidir. Sınıflandırma klinik bulgular, histoloji ve immünfenotiplemedeki korelasyon ileyapılır.Tedavi seçenekleri cilde yönelik tedaviler, immünmodülatör veya düşük dozimmünsupresif tedavileri içerir. Agresif seyirli nadir vakalarda sistemik çok ilaçlı kemoterapigerekebilir. Bu derlemenin amacı T, B, ve NK lenfositlerinin ontogenisini tanımlamak ve DünyaSağlık Örgütü ile Avrupa Kanser Araştırma ve Tedavi Örgütünün kutanöz lenfomalar içinönerdiği en çok kabul gören sınıflandırmayı detaylandırmaktır. Kutanöz lenfomaların tedavisi dekısaca tartışılacaktır.

Kutanöz lenfomalar: Derleme

Skin may be affected by non-Hodgkin lymphomas, and it is the second most frequently involvedextranodal organ, after the gastrointestinal tract. Cutaneous lymphomas may originate from T, B,or NK lymphocytes. Diagnosis is difficult, and knowledge of these diseases is important to ensuretheir detection and adequate treatment and follow-up. Clinical picture is heterogeneous, and his- tology is essential to confirm the diagnosis. The classification is given by the correlation betweenclinical findings, histology and immunophenotyping. Therapeutic options include skin-directedtherapies, immunomodulatory or low-dose immunosuppressive drugs. Rare cases of aggressivedisease require systemic multidrug chemotherapy. The purpose of this review is to describe theontogeny of T, B and NK lymphocytes, and to detail the most accepted classification of cutaneouslymphomas, proposed by the World Health Organisation and European Organisation for Researchand Treatment of Cancer. Treatment of cutaneous lymphomas will be briefly discussed.

PDF

___

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz- Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ. WHO- EORTC Blood 2005; 105: 3768- 85.
2. De Moricz CZM, Sanches Jr JA. Lymphoproliferative processes of the skin. Part 1-Primary cutaneous B-cell lymphomas. An Bras Der- matol 2005; 80: 461-71.
3. Sanches Jr JA, de Moricz CZM, Neto CF. Lymphoproliferative processes of the skin. Part 2- Cutaneous T-cell and NK-cell lymphomas. An Bras Dermatol 2006; 81: 7-25.
4. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, Diaz-Peréz JL, Geerts ML, Goos M, Knobler R, Ralfkiaer E, San- tucci M, Smith N, Wechsler J, van Vloten WA, Meijer CJ. EORTC classification for primary cutane- ous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organiza- tion for Research and Treatment of Cancer. Blood 1997; 90: 354-71.
5. Jaffe ES, Harris NL, Stein H, Var- diman JW (Eds). World Health Organization classification of tu- mors: Pathology and genetics of tumours of hematopoietic and lymphoid tissues. Ann Oncol 2002; 13: 490-1.
6. Slater DN. The new World Health OrganizationEuropean Organiza- tion for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol 2005; 153: 874-80.
7. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkins lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92: 1240-51.
8. Bradford PT, Devesa SS, Ander- son WF, Toro JR. Cutaneous lym- phoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064-73.
9. Rothemberg EV. T-lineage speci- fication and commitment: A gene regulation perspective. Semin Im- munol 2002; 14: 431-40.
10. Kupper TS, Fuhlbrigge RC. Im- mune surveillance in the skin: mechanisms and clinical conse- quences. Nat Rev Immunol 2004; 4: 211-22.
11. Ichii M. Early B lymphocyte de- velopment: Similarities and differ- ences in human and mouse. World J Stem Cells 2014; 6: 421-31.
12. Smoller BR, Santucci M, Wood GS, Whittaker SJ. Histopathology and genetics of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003; 17: 1277-311.
13. Fung MA, Murphy MJ, Hoss DM, Grant-Kels JM. Practical evalua- tion and management of cutaneous lymphoma. J Am Acad Dermatol 2002; 46: 325-60.
14. Ponti R, Quaglino P, Novelli M, Fierro MT, Comessatti A, Peroni A, Bonello L, Bernengo MG. T- cell receptor γ gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: Correlation with clinical, histological and immunophe- notypical findings. Br J Dermatol 2005; 153: 565-73.
15. Chitgopeker P, Sahni D. T-cell re- ceptor gene rearrangement detec- tion in suspected cases of cutane- ous T-cell lymphoma. J Invest Dermatol 2014; 134: 19.
16. Nagler AR, Samimi S, Schaffer A, Vittorio CC, Kim EJ, Rook AH. Peripheral blood findings in erythrodermic patients: Importance for the differential diagnosis of Sézary syndrome. J Am Acad Dermatol 2012; 66: 503-8.
17. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pit- telkow M, Bernengo MG, Sterry W, Laroche L, Trautinger F, Whit- taker S. Revisions to the staging and classification of mycosis fun- goides and Sézary syndrome: A proposal of the International So- ciety for Cutaneous Lymphomas (ISCL) and the cutaneous lym- phoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-22.
18. Verdonck K, González E, Van Dooren S, Vandamme A-M, Vanham G, Gotuzzo E. Human T- lymphotropic virus 1: Recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7: 266-81.
19. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: A biologic rationale for their distinct clinical behaviors. Blood 2010; 116: 767- 71.
20. Desai M, Liu S, Parker S. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: A single-institution cohort. J Am Acad Dermatol 2015; 72: 276-85.
21. Ahn CS, ALSayyah A, Sangüeza OP. Mycosis fungoides: An updat- ed review of clinicopathologic var- iants. Am J Dermatopathol 2014; 36: 933-48.
22. Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic fac- tors in transformed mycosis fun- goides: a retrospective analysis of 100 cases. Blood 2012; 119: 1643- 9.
23. Guitart J, Kennedy J, Ronan S, Chmiel JS, Hsiegh Y-C, Variakojis D. Histologic criteria for the diagnosis of mycosis fungoides: Proposal for a grading system to standardize pathology reporting. J Cutan Pathol 2001; 28: 174-83.
24. Salhany KE, Cousar JB, Greer JP, Casey TT, Fields JP, Collins RD. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immuno- logic study. Am J Pathol 1988; 132: 265-77.
25. Dewar R, Andea AA, Guitart J, Arber DA, Weiss LM. Best prac- tices in diagnostic immunohisto- chemistry: workup of cutaneous lymphoid lesions in the diagnosis of primary cutaneous lymphoma. Arch Pathol Lab Med 2015; 139: 338-50.
26. Zhang Y, Wang Y, Yu R, Huang Y, Su M, Xiao C, Martinka M, Dutz JP, Zhang X, Zheng Z, Zhou Y. Molecular markers of early- stage mycosis fungoides. J Invest Dermatol 2012; 132: 1698-706.
27. Ponte P, Serrão V, Apetato M. Ef- ficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides: nbUVB vs. PUVA in early-stage MF. J Eur Acad Dermatol Venereol 2009; 24: 716-21.
28. Harrison C, Young J, Navi D, Riaz N, Lingala B, Kim Y, Hoppe R. Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 2011; 81: 651-7.
29. Wu PA, Huang V, Bigby ME. In- terventions for mycosis fungoides: Critical commentary on a Cochrane Systematic Review. Br J Dermatol 2014; 170: 1015-20.
30. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Pri- mary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). J Am Acad Dermatol 2014; 70: 205-16.
31. Schlaak M, Theurich S, Pickenhain J, Skoetz N, Kurschat P, von Bergwelt-Baildon M. Allogeneic stem cell transplantation for ad- vanced primary cutaneous T-cell lymphoma: A systematic review. Crit Rev Oncol Hematol 2013; 85: 21-31.
32. Demirkesen C, Esirgen G, Engin B, Songur A, Oğuz O. The clinical features and histopathologic pat- terns of folliculotropic mycosis fungoides in a series of 38 cases: Clinical features of FMF. J Cutan Pathol 2015; 42: 22-31.
33. Marschalkó M, Erős N, Kontár O, Hidvégi B, Telek J, Hársing J, Jókai H, Bottlik G, Rajnai H, Szepesi A, Matolcsy A, Kárpáti S, Csomor J. Folliculotropic mycosis fungoides: clinicopathological analysis of 17 patients. J Eur Acad Dermatol Venereol 2014; 18.
34. Van Doorn R, Scheffer E, Wil- lemze R. Follicular mycosis fun- goides: A distinct disease entity with or without associated follicu- lar mucinosis. Arch Dermatol 2001; 138: 191-8.
35. Haghighi B, Smoller BR, LeBoit PE, Warnke RA, Sander CA, Kohler S. Pagetoid reticulosis: An immunophenotypic, molecular, and clinicopathologic study. Mod Pathol 2000; 13: 502-10.
36. Tsuruta D, Kono T, Kutsuna H, Yashiro N, Ishii M. Granuloma- tous slack skin: An ultrastructural study. J Cutan Pathol 2001; 28: 44-8.
37. Clarijs M, Poot F, Laka A, Pirard C, Bourlond A. Granulomatous slack skin: Reatment with exten- sive surgery and review of the lit- erature. Dermatology 2003; 206: 393-7.
38. van Haselen CW, Toonstra J, van der Putte SJ, van Dongen JJ, van Hees CL, van Vloten WA. Granu- lomatous slack skin: Report of three patients with an updated re- view of the literature. Dermatolo- gy 1998; 196: 382-91.
39. Castano E, Glick S, Wolgast L, Naeem R, Sunkara J, Elston D, Ja- cobson M. Hypopigmented myco- sis fungoides in childhood and ad- olescence: A long-term retrospec- tive study: Hypopigmented MF in childhood. J Cutan Pathol 2013; 40: 924-34.
40. Furlan FC, de Paula Pereira BA, da Silva LF, Sanches JA. Loss of melanocytes in hypopigmented mycosis fungoides: A study of 18 patients: Loss of melanocytes in MF. J Cutan Pathol 2014; 41: 101- 7.
41. Furlan FC, Sanches JA. Hypopig- mented mycosis fungoides: A re- view of its clinical features and pathophysiology. An Bras Derma- tol 2013; 88: 954-60.
42. Abbott RA, Sahni D, Robson A, Agar N, Whittaker S, Scarisbrick JJ. Poikilodermatous mycosis fun- goides: A study of its clinicopatho- logical, immunophenotypic, and prognostic features. J Am Acad Dermatol 2011; 65: 313-9.
43. Shiomi T, Monobe Y, Kuwabara C, Hayashi H, Yamamoto T, Sa- dahira Y. J Cutan Pathol 2013; 40: 317-20.
44. Vonderheid EC. On the diagnosis of erythrodermic cutaneous T-cell lymphoma. J Cutan Pathol 2006; 33: 27-42.
45. Kubica AW, Davis MD, Weaver AL, Killian JM, Pittelkow MR. Sézary syndrome: A study of 176 patients at Mayo Clinic. J Am Acad Dermatol 2012; 67: 1189-99.
46. Pal S, Haroon TS. Erythroderma: A clinico-etiologic study of 90 cases. Int J Dermatol 1998; 37: 104-7.
47. Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: An analysis of prog- nostic factors in a cohort of pa- tients with erythrodermic cutane- ous T-cell lymphoma. Int J Derma- tol 2009; 48: 243-52.
48. Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wil- son LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins- Hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: Im- munopathogenesis, literature re- view of therapeutic options, and recommendations for therapy by the United States Cutaneous Lym- phoma Consortium (USCLC). J Am Acad Dermatol 2011; 64: 352- 404.
49. Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiv- ing allogeneic or autologous hema- topoietic stem cell transplant in mycosis fungoides and sézary syn- drome. Biol Blood Marrow Trans- plant 2009; 15: 982-90.
50. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. Cd30+cutaneous lymphoprolifera- tive disorders: The stanford expe- rience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 2003; 49: 1049-58.
51. DeCouteau JF, Butmarc JR, Kin- ney MC, Kadin ME. The t(2;5) chromosomal translocation is not a common feature of primary cuta- neous CD30 lymphoproliferative disorders: comparison with ana- plastic large cell lymphoma of nodal origin. Blood 1996; 87: 3437-41.
52. Bekkenk MW, Geelen FA, van Voorst VPC, Heule F, Geerts ML, van Vloten WA, Meijer CJ, Wil- lemze R. A report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients. Blood 2000; 95: 3653-61.
53. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996; 34: 470-480.
54. Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, Olsen E, Kim YH, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Cerroni L, Berti E, Horwitz S, Prince HM, Guitart J, Estrach T, Sanches JA, Duvic M, Ranki A, Dreno B, Ostheeren- Michaelis S, Knobler R, Wood G, Willemze R. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lym- phoproliferative disorders: lym- phomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118: 4024-35.
55. Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphopro- liferative disorders. Clin Cancer Res 2009; 15: 6217-24.
56. El Shabrawi-Caelen L, Kerl H, Cerroni L. Lymphomatoid papulo- sis: Reappraisal of clinicopatho- logic presentation and classification into subtypes A, B, and C. Arch Dermatol 2004; 140: 441-7.
57. Kadin M, Nasu K, Sako D, Said J, Vonderheid E. Lymphomatoid papulosis. A cutaneous prolifera- tion of activated helper T cells ex- pressing Hodgkins disease- associated antigens. Am J Pathol 1985; 119: 315-25.
58. Marzano AV, Berti E, Paulli M, Caputo R. Cytophagocytic histio- cytic panniculitis and subcutane- ous panniculitis-like T-cell lym- phoma. Arch Dermatol 2000; 136: 889-96.
59. Hoque SR, Child FJ, Whittaker SJ, Ferreira S, Orchard G, Jenner K, Spittle M, Russell-Jones R. Subcu- taneous panniculitis-like T-cell lymphoma: A clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol 2003; 148: 516-25.
60. Takeshita M, Imayama S, Oshiro Y, Kurihara K, Okamoto S, Matsuki Y, Nakashima Y, Okamura T, Shiratsuchi M, Hayashi T, Kikuchi M. Clinicopathologic analysis of 22 cases of subcutane- ous panniculitis-like CD56- or CD56+lymphoma and review of 44 other reported cases. Am J Clin Pathol 2004; 121: 408-16.
61. Bosisio F, Boi S, Caputo V, Chi- arelli C, Oliver F, Ricci R, Cerroni L. Lobular panniculitic infiltrates With overlapping histopathologic features of lupus panniculitis (lu- pus profundus) and subcutaneous T-cell lymphoma: a conceptual and practical dilemma. Am J Surg Pathol 2015; 39: 206-11.
62. Lee WS, Hwang JH, Kim MJ, Go SI, Lee A, Song HN, Lee MJ, Kang MH, Kim HG, Lee JH. Cy- closporine A as a primary treat- ment for panniculitis-like T cell lymphoma: a case with a longterm remission. Cancer Res Treat 2014; 46: 312-6.
63. Guenova E, Schanz S, Hoetzenecker W, DeSimone JA, Mehra T, Voykov B, Urosevic- Maiwald M, Berneburg M, Dummer R, French LE, Kerl K, Kama- rashev J. Fierlbeck G, Cozzio A. Systemic corticosteroids for sub- cutaneous panniculitis-like T-cell lymphoma. Br J Dermatol. 2014; 171: 891-4.
64. Bekkenk MW. CD56+hematological neoplasms presenting in the skin: A retrospec- tive analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004; 15: 1097-108.
65. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol 2003; 40: 175-84.
66. Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, Cheung MM, Lau WH. Nonnasal lympho- ma expressing the natural killer cell marker CD56: A clinicopatho- logic study of 49 cases of an un- common aggressive neoplasm. Blood 1997; 89: 4501-13.
67. Natkunam Y, Smoller BR, Zehnder JL, Dorfman RF, Warnke RA. Aggressive cutaneous NK and NK-like T-cell lymphomas: clini- copathologic, immunohistochemi- cal, and molecular analyses of 12 cases. Am J Surg Pathol 1999; 23: 571-81.
68. Jhuang JY, Chang ST, Weng SF, Pan ST, Chu PY, Hsieh PP, Wei CH, Chou SC, Koo CL, Chen CJ, Hsu JD, Chuang SS. Extranodal natural killer/T-cell lymphoma, nasal type in Taiwan: a relatively higher frequency of T-cell lineage and poor survival for extranasal tumors. Hum Pathol 2015; 46: 313-21.
69. Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, Ng CS, Ngan RK. Primary non-Hodgkins lym- phoma of the nose and nasophar- ynx: Clinical features, tumor im- munophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 70-7.
70. Takata K, Hong M, Sitthi- namsuwan P, Loong F, Tan SY, Liau JY, Hsieh PP, Ng SB, Yang SF, Pongpruttipan T, Suk- panichnant S, Kwong YL, Hyeh Ko Y, Cho YT, Chng WJ, Matsu- shita T, Yoshino T, Chuang SS. Primary cutaneous NK/T-cell lymphoma, nasal type and CD56- positive peripheral T-cell lym- phoma: A cellular lineage and clinicopathologic study of 60 pa- tients from Asia. Am J Surg Pathol 2015; 39: 1-12.
71. Lu D, Patel KA, Duvic M, Jones D. Clinical and pathological spec- trum of CD8-positive cutaneous T- cell lymphomas. J Cutan Pathol 2002; 29: 465-72.
72. Nofal A, Abdel-Mawla MY, Assaf M, Salah E. Primary cutaneous aggressive epidermotropic CD8+T-cell lymphoma: Proposed diagnostic criteria and therapeutic evaluation. J Am Acad Dermatol 2012; 67: 748-59.
73. Berti E, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Wil- lemze R. Primary cutaneous CD8- positive epidermotropic cytotoxic T cell lymphomas: A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999; 155: 483-92.
74. Nakamizo S, Egawa G, Tomura M, Sakai S, Tsuchiya S, Kitoh A, Honda T, Otsuka A, Nakajima S, Dainichi T, Tanizaki H, Mitsuya- ma M, Sugimoto Y, Kawai K, Yo- shikai Y, Miyachi Y, Kabashima K. Dermal Vγ4 (+) γδ T cells pos- sess a migratory potency to the draining lymph nodes and modu- late CD8 (+) T-cell activity through TNF-α production. J In- vest Dermatol 2015; 135: 1007-15.
75. Berti E, Cerri A, Cavicchini S, De- lia D, Soligo D, Alessi E, Caputo R. Primary cutaneous gamma/delta lymphoma presenting as dissemi- nated pagetoid reticulosis. J Invest Dermatol 1991; 96: 718-23.
76. Harrington L, Sokol L, Holdener S, Shao H, Zhang L. Cutaneous gamma-delta T-cell lymphoma with central nervous system in- volvement: report of a rarity with review of literature: Cutaneous γδ T-cell lymphoma involving CNS. J Cutan Pathol 2014; 41: 936-43.
77. Alexander RE, Webb AR, Abuel- Haija M, Czader M. Rapid pro- gression of primary cutaneous gammadelta T-cell lymphoma with an initial indolent clinical presentation. Am J Dermatopathol 2014; 36: 839-42.
78. de Wolf-Peeters C, Achten R. Gamma-delta T-cell lymphomas: a homogeneous entity? Histopathol- ogy 2000; 36: 294-305.
79. Toro JR. Gamma-delta T-cell phe- notype is associated with signifi- cantly decreased survival in cuta- neous T-cell lymphoma. Blood 2003; 101: 3407-12.
80. Bekkenk MW. Peripheral T-cell lymphomas unspecified presenting in the skin: Analysis of prognostic factors in a group of 82 patients. Blood 2003; 102: 2213-9.
81. Beltraminelli H, Leinweber B, Kerl H, Cerroni L. Primary cuta- neous CD4+small-/medium-sized pleomorphic T-cell lymphoma: A cutaneous nodular proliferation of pleomorphic T lymphocytes of un- determined significance? A study of 136 cases. Am J Dermatopathol 2009; 31: 317-22.
82. Friedmann D, Wechsler J, Delfau MH, Estève E, Farcet JP, de Muret A, Parneix-Sparke A, Vaillant L, Revuz J, Bagot M. Primary cuta- neous pleomorphic small T-cell lymphoma. Arch Dermatol 1995; 131: 1009-15.
83. Beljaards RC, Meijer CJ, van der Putte SC, Hollema H, Geerts ML, Bezemer PD, Willemze R. Primary cutaneous T-cell lymphomas: clinicopathologic features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lympho- ma. J Pathol 1994; 172: 53-60.
84. Grange F, Hedelin G, Joly P, Beylot-Barry M, DIncan M, De- launay M, Vaillant L, Avril MF, Bosq J, Wechsler J, Dalac S, Gro- sieux C, Franck N, Esteve E, Michel C, Bodemer C, Vergier B, Laroche L, Bagot M. Prognostic factors in primary cutaneous lym- phomas other than mycosis fun- goides and the Sézary syndrome. Blood 1999; 93: 3637-42.
85. Tokura Y, Sawada Y, Shimauchi T. Skin manifestations of adult T- cell leukemia/lymphoma: Clinical, cytological and immunological features. J Dermatol 2014; 41: 19- 25.
86. Shimoyama M. Diagnosis criteria and classification of clinical sub- types of adult T-cell leukemia- lymphoma: A report from the Lymphoma Study Group. Br J Haematol 1991; 79: 428-37.
87. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T, Shimoyama M. A new G-CSF- supported combination chemother- apy, LSG15, for adult T-cell leu- kaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001; 113: 375-82.
88. Sawada Y, Hino R, Hama K, Ohmori S, Fueki H, Yamada S, Fukamachi S, Tajiri M, Kubo R, Yoshioka M, Nakashima D, Sugita K, Yoshiki R, Shimauchi T, Mori T, Izu K, Kobayashi M, Nakamura M, Tokura Y. Type of skin erup- tion is an independent prognostic indicator for adult T-cell leuke- mia/lymphoma. Blood 2011; 117: 3961-7.
89. Ohshima K, Suzumiya J, Sato K, Kanda M, Sugihara M, Haraoka S, Takeshita M, Kikuchi M. Nodal T- cell lymphoma in an HTLV-I en- demic area: Proviral HTLV-I DNA, histological classification and clinical evaluation. Br J Hae- matol 1998; 101: 703-11.
90. Ishida T, Jo T, Takemoto S, Su- zushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwa- ra H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miya- moto T, Akinaga S, Tomonaga M, Ueda R. Dose-intensified chemo- therapy alone or in combination with mogamulizumab in newly di- agnosed aggressive adult T-cell leukaemia-lymphoma: A random- ized phase II study. Br J Haematol 2015 in press.
91. Jacob MC, Chaperot C, Mossuz P, Feuillard J, Valensi F, Leroux D, Béné MC, Bensa JC, Brière F, Plumas J. CD4 CD56 lineage neg- ative malignancies: A new entity developed from malignant early plasmacytoid dendritic cells. Hae- matologica 2003; 88: 941-55.
92. Wang W, Li W, Jia JJ, Zheng Y, Wang H, Gao XM, Dong XY, Tian Q, Jing HL, Wang X, Xiao SX. Blastic plasmacytoid dendritic cell neoplasm: A case report. On- col Lett 2015; 9: 1388-92.
93. Park SH, Chi HS, Cho YU, Jang S, Park CJ. Leukemic manifestation of blastic plasmacytoid dendritic cell neoplasm: laboratory ap- proaches in 2 cases. Blood Res 2014; 49: 198-200.
94. Petrella T, Comeau MR, Maynadié M, Couillault G, De Muret A, Maliszewski CR, Dalac S, Durlach A, Galibert L. Agranular CD4+CD56+hematodermic neo- plasm(blastic NK-cell lymphoma) originates from a population of CD56+precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002; 26: 852-62.
95. Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecu- lar biology, diagnosis, and therapy. Cancer Control 2014; 21: 279-89.
96. Pham-Ledard A, Cowppli-Bony A, Doussau A, Prochazkova-Carlotti M, Laharanne E, Jouary T, Belaud-Rotureau MA, Vergier B, Merlio JP, Beylot-Barry M. Diag- nostic and prognostic value of BCL2 rearrangement in 53 patients with follicular lymphoma present- ing as primary skin lesions. Am J Clin Pathol 2015; 143: 362-73.
97. Crosti A. Micosi fungoide e reticu- loistiocitomi cutanei maligni. Mi- nerva Dermat 1951; 26: 3-11.
98. De Leval L, Harris NL, Longtine J, Ferry JA, Duncan LM. Cutaneous B-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differ- ential diagnosis and classification. A J Surg Pathol 2001; 25: 732-41.
99. Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, Burg G, von Den Driesch P, Dummer R. Reduction of tumor burden and stabilization of disease by systemic therapy with anti- CD20 antibody (rituximab) in pa- tients with primary cutaneous B- cell lymphoma. Cancer 2000; 89: 1835-44.
100. Paul T, Radny P, Kröber SM, Paul A, Blaheta H-J, Garbe C. Intralesional rituximab for cutane- ous B-cell lymphoma. Br J Derma- tol 2001; 144: 1239-43.
101. Wilcox RA. Cutaneous B- cell lymphomas: 2015 update on diagnosis, risk-stratification, and management. Am J Hematol 2015; 90: 73-6.
102. Cerroni L, Zöchling N, Pütz B, Kerl H. Infection by Bor- relia burgdorferi and cutaneous B- cell lymphoma. J Cutan Pathol 1997; 24: 457-61.
103. Goyal A, Moore JB, Gim- bel D, Carter JB, Kroshinsky D, Ferry JA, Harris NL, Duncan LM. PD-1, S-100 and CD1a expression in pseudolymphomatous folliculi- tis, primary cutaneous marginal zone B-cell lymphoma (MALT lymphoma) and cutaneous lym- phoid hyperplasia: PD-1 and CD1a in lymphoma and pseudolympho- ma. J Cutan Pathol 2015; 42: 6-15.
104. Zenahlik P, Fink-Puches R, Kapp KS, Kerl H, Cerroni L. Die Therapie der primären kutanen B-Zell-Lymphome. Der Hautarzt 2000; 51: 19-24.
105. Soda R, Constanzo A, Cantonetti M, Orlandi A, Bianchi L, Chimenti S. Systemic therapy of primary cutaneous B-cell lym- phoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. Acta Derm Venereol 2001; 81: 207-8.
106. Kim MJ, Hong ME, Maeng CH, Jung HA, Hong JY, Choi MK, Kim SJ, Ko YH, Kim WS. Clinical features and treat- ment outcomes of primary cutane- ous B-cell lymphoma: a single- center analysis in South Korea. Int J Hematol 2015; 101: 273-8.
107. Vermeer MH, Geelen FAMJ, van Haselen CW, van Voorst Vader PC, Geerts ML, val Vloten WA, Willemze R. Primary cutaneous large B-cell lymphomas of the legs: A distinct type of cuta- neous B-cell lymphoma with an intermediate prognosis. Arch Dermatol 1996; 132: 1304-8.
108. Grange F, Bekkenk MW, Wechsler J, Meijer C, Cerroni L, Bernengo M, Bosq J, Hedelin G, Fink Puches R, van Vloten WA, Joly P, Bagot M, Willemze R. Prognostic factors in primary cuta- neous large B-cell lymphomas: a European multicenter study. J Clin Oncol 2001; 19: 3602-10.
109. Hoefnagel JJ, Vermeer MH, Janssen PM, Fleuren GJ, Meijer CJLM, Willemze R. Bcl-2, Bcl-6 and CD10 expression in cu- taneous B-cell lymphoma: Further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol 2003; 149: 1183-91.
110. Brogan BL, Zic JA, Kin- ney MC, Hu JY, Hamilton KS, Greer JP. Large B-cell lymphoma of the leg: Clinical and pathologic characteristics in a north american series. J Am Acad Dermatol 2003; 49: 223-8.
111. Suárez AL, Pulitzer M, Horwitz S, Moskowitz A, Querfeld C, Myskowski PL. Primary cuta- neous B-cell lymphomas: Part I. Clinical features, diagnosis, and classification. J Am Acad Derma- tol 2013; 69: 1-13.
112. Perniciaro C, Winkelmann RK, Daoud MS, Su WPD. Malig- nant angioendotheliomatosis is an press
113. angiotropic intravascular lymphoma: Immunohistochemical, ultrastructural and molecular ge- netic studies. Am J Dermatopathol 1995; 17: 242-8.
114. Nguyen GH, Yassin AH, Magro CM. Unusual variants of intravascular malignant hemato- poietic neoplasms: A report of 4 cases and review of the literature. Am J Dermatopathol 2015 in press.
115. Ferreri AJM, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, Zucca E, Rossi G, López-Guillermo A, Pavlovsky MA, Geerts ML, Candoni A, Lestani M, Asioli S, Milani M, Piris MA, Pileri S, Facchetti F, Cavalli F, Ponzoni M. Intravascu- lar lymphoma: clinical presenta- tion, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the cutaneous variant. Br J Haematol 2004; 127: 173-83.